ZIOPHARM Oncology Inc (ZIOP) Shares are Up 8.24%

ZIOPHARM Oncology Inc (ZIOP) has been under a strong bear grip, hence the stock is down -21.11% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 8.31% in the past 1 week. The stock has risen by 8.24% in the past week indicating that the buyers are active at lower levels, but the stock is down -18.46% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 8.48% and the 50-Day Moving Average is 20.36%. ZIOPHARM Oncology, Inc. has dropped 38.17% during the last 3-month period . Year-to-Date the stock performance stands at -41.52%.


ZIOPHARM Oncology Inc (NASDAQ:ZIOP): stock turned positive on Friday. Though the stock opened at $4.83, the bulls momentum made the stock top out at $4.92 level for the day. The stock recorded a low of $4.69 and closed the trading day at $4.86, in the green by 0.83%. The total traded volume for the day was 1,342,729. The stock had closed at $4.82 in the previous days trading.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.